Phenotypes associated with this allele

• Allele Symbol: Marchf7^{Gt(ROSABetageo)1Summ}
• Allele Name: gene trap 1, Su M Metcalfe
• Allele ID: MGI:3530008
• Summary: 2 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Marchf7^Gt(ROSABetageo)1Summ/Marchf7^Gt(ROSABetageo)1Summ	involves: BALB/c	MGI:3576474
ht2	Marchf7^Gt(ROSABetageo)1Summ/Marchf7^+	involves: BALB/c	MGI:3576475

Genotype
MGI:3576474

hm1

• Allelic Composition: Marchf7^{Gt(ROSABetageo)1Summ}/Marchf7^{Gt(ROSABetageo)1Summ}
• Genetic Background: involves: BALB/c

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

nervous system

abnormal corpus callosum morphology ( J:96167 )

• agenesis of the corpus callosum during development

abnormal spinal cord morphology ( J:96167 )

• degeneration of substantia gelatinosa lamina II axons in adulthood

neurodegeneration ( J:96167 )

• degeneration of substantia gelatinosa lamina II axons in adulthood

immune system

increased T cell proliferation ( J:96167 )

• hyper-proliferation of T cells, with a greater proportion of T cells entering the cell cycle in response to ConA, however showed minimal effects on B cell proliferation

• normal spleen, thymus, kidney, lung and development of T and B lymphocytes

abnormal interleukin level ( J:96167 )

• 2-fold increase in IL-2 following ConA treatment but not in response to LPS

abnormal cytokine secretion ( J:96167 )

• increased release of T cell-derived leukaemia inhibitory factor (LIF), a neuropoietic cytokine, from ConA stimulated spleen cells

increased interleukin-10 secretion ( J:96167 )

• 10-fold increase in IL-10 release in response to the mitogen, ConA, but not to LPS

hematopoietic system

increased T cell proliferation ( J:96167 )

• hyper-proliferation of T cells, with a greater proportion of T cells entering the cell cycle in response to ConA, however showed minimal effects on B cell proliferation

• normal spleen, thymus, kidney, lung and development of T and B lymphocytes

homeostasis/metabolism

abnormal interleukin level ( J:96167 )

• 2-fold increase in IL-2 following ConA treatment but not in response to LPS

cellular

increased T cell proliferation ( J:96167 )

• hyper-proliferation of T cells, with a greater proportion of T cells entering the cell cycle in response to ConA, however showed minimal effects on B cell proliferation

• normal spleen, thymus, kidney, lung and development of T and B lymphocytes

Genotype
MGI:3576475

ht2

• Allelic Composition: Marchf7^{Gt(ROSABetageo)1Summ}/Marchf7⁺
• Genetic Background: involves: BALB/c

immune system

increased T cell proliferation ( J:96167 )

abnormal interleukin level ( J:96167 )

• 2-fold increase in IL-2 following ConA treatment but not in response to LPS

abnormal cytokine secretion ( J:96167 )

• increased release of T cell-derived leukaemia inhibitory factor (LIF), a neuropoietic cytokine, from ConA stimulated spleen cells

increased interleukin-10 secretion ( J:96167 )

• 10-fold increase in IL-10 release in response to the mitogen, ConA, but not to LPS

hematopoietic system

increased T cell proliferation ( J:96167 )

homeostasis/metabolism

abnormal interleukin level ( J:96167 )

• 2-fold increase in IL-2 following ConA treatment but not in response to LPS

cellular

increased T cell proliferation ( J:96167 )